Treating T24 cells with erianin restores gefitinib drug sensitivity by regulating MYLK to inhibit EGFR and EMT processes.

IF 3.1 3区医学 Q2 ONCOLOGY

American journal of cancer research Pub Date : 2026-08-15 eCollection Date: 2026-01-01 DOI:10.62347/YZXW4438

Fubo Li, Yan Guo, Zhuangyu Xu, Wenxin Li, Yi Dong, Fan Xu

引用次数: 0

Abstract

Erianin exerts anticancer effects in bladder cancer, although its underlying molecular mechanisms remain unclear. This study used online databases to identify erianin-related drug targets and bladder cancer-associated disease targets and to predict the potential signaling pathways involved. Intersecting genes were enriched in the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor resistance signaling pathway, and high myosin light chain kinase (MYLK) expression was associated with poor prognosis. A gefitinib-resistant bladder cancer cell line was established to evaluate the role of MYLK. Erianin inhibited MYLK and EGFR protein expression, blocked EGFR signaling and epithelial-mesenchymal transition (EMT), restored gefitinib sensitivity, and suppressed the proliferation, invasion, and migration of bladder cancer cells.

查看原文本刊更多论文

用缬氨酸处理T24细胞，通过调节MYLK抑制EGFR和EMT过程，恢复吉非替尼药物敏感性。

灯盏花素在膀胱癌中发挥抗癌作用，尽管其潜在的分子机制尚不清楚。本研究使用在线数据库识别羊角胺相关药物靶点和膀胱癌相关疾病靶点，并预测潜在的信号通路。交叉基因在表皮生长因子受体（EGFR）酪氨酸激酶抑制剂耐药信号通路中富集，肌球蛋白轻链激酶（MYLK）高表达与预后不良相关。建立耐吉非替尼膀胱癌细胞系，评价MYLK的作用。Erianin抑制MYLK和EGFR蛋白表达，阻断EGFR信号传导和上皮间质转化（epithelial-mesenchymal transition， EMT），恢复吉非替尼敏感性，抑制膀胱癌细胞的增殖、侵袭和迁移。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of cancer research ONCOLOGY-

自引率

3.80%

发文量

263

期刊介绍： The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.